Article
Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3).
Molecular cell - 5 Apr 2018
Lin Wei, Das Kalyan, Degen David, Mazumder Abhishek, Duchi Diego, Wang Dongye, Ebright Yon W, Ebright Richard Y, Sineva Elena, Gigliotti Matthew, Srivastava Aashish, Mandal Sukhendu, Jiang Yi, Liu Yu, Yin Ruiheng, Zhang Zhening, Eng Edward T, Thomas Dennis, Donadio Stefano, Zhang Haibo, Zhang Changsheng, Kapanidis Achillefs N, Ebright Richard H
Abstract excerpt
Fidaxomicin is an antibacterial drug in clinical use for treatment of Clostridium difficile diarrhea. The active ingredient of fidaxomicin, lipiarmycin A3 (Lpm), functions by inhibiting bacterial RNA polymerase (RNAP). Here we report a cryo-EM structure of Mycobacterium tuberculosis RNAP holoenzyme in complex with Lpm at 3.5-Å resolution. The structure shows that Lpm binds at the base of the RNAP "clamp." The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.